XERAVA

PeakSM

eravacycline

RAPHAS
NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Oct 19, 2037
141 months away
Patent Expiry
Oct 19, 2037
Exclusivity Expiry
Aug 27, 2028

Patent Records (4)

Patent #ExpiryTypeUse Code
8796245
Aug 7, 2029
U-2380
8906887
Dec 28, 2030
Product
—
10961190
Oct 19, 2037
Substance
—
11578044
Oct 19, 2037
Substance
—
Company
RAPHAS
RAPHAS
Korea - Seoul
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers